cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Atreca Inc
15 own
25 watching
Current Price
$1.61
$-0.05
(-3.01%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
62.9M
52-Week High
52-Week High
5.36
52-Week Low
52-Week Low
0.7595
Average Volume
Average Volume
0.09M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization62.9M
icon52-Week High5.36
icon52-Week Low0.7595
iconAverage Volume0.09M
iconDividend Yield--
iconP/E Ratio--
What does the Atreca Inc do?
Atreca Inc is a biopharmaceutical company utilizing a differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. Their approach relies on the human immune system to direct them to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. They believe the fact that their approach has the potential to deliver novel, previously unexplored immuno-oncology targets provides them with a significant competitive advantage over traditional approaches which focus on known targets that many companies are aware of and can pursue. They have utilized their drug discovery approach to identify over 1,400 distinct human antibodies that bind preferentially to tumor tissue from patients who are not the source of the antibody. Their lead product candidate, ATRC-101, is a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using their discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It has demonstrated robust anti-tumor activity as a single agent in multiple preclinical models, including one model in which PD-1 checkpoint inhibitors typically display limited activity. They anticipate filing an Investigational New Drug, or IND, application for ATRC-101 in late 2019 and initiating a Phase 1b clinical trial in patients with solid tumors in early 2020, subject to U.S. Food and Drug Administration, or FDA, approval of their IND application. They were incorporated under the laws of the state of Delaware in 2010 under the name Atreca, Inc. Their principal executive offices are located at 500 Saginaw Drive, Redwood City, CA 94063.
Read More
How much money does Atreca Inc make?
News & Events about Atreca Inc.
Globe Newswire
3days ago
SAN CARLOS, Calif., and MONROVIA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, ...
Globe Newswire
1month ago
SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the ...
Zolmax
5 months ago
Atreca, Inc. (NASDAQ:BCEL Get Rating) saw a significant drop in short interest in August. As of August 15th, there was short interest totalling 2,730,000 shares, a drop of 7.8% from the July 31st total of 2,960,000 shares. Approximately 9.7% of the shares of the company are short sold. Based...
Zolmax
8 months ago
Atreca (NASDAQ:BCEL Get Rating) had its price objective dropped by research analysts at Robert W. Baird from $12.00 to $9.00 in a research note issued on Thursday, The Fly reports. Robert W. Bairds price objective suggests a potential upside of 389.13% from the stocks previous close. A number of ...
Ticker Report
10 months ago
Equities research analysts expect Atreca, Inc. (NASDAQ:BCEL Get Rating) to report earnings of ($0.78) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Atrecas earnings, with estimates ranging from ($0.82) to ($0.72). Atreca ...
Frequently Asked Questions
Frequently Asked Questions
What is Atreca Inc share price today?
plus_minus_icon
Can Indians buy Atreca Inc shares?
plus_minus_icon
How can I buy Atreca Inc shares from India?
plus_minus_icon
Can Fractional shares of Atreca Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Atreca Inc stocks?
plus_minus_icon
What is today’s traded volume of Atreca Inc?
plus_minus_icon
What is today’s market capitalisation of Atreca Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Atreca Inc?
plus_minus_icon
What percentage is Atreca Inc down from its 52-Week High?
plus_minus_icon
What percentage is Atreca Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.61
$-0.05
(-3.01%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00